SHANGHAI, April 22,
2024 /PRNewswire/ -- Brise Pharmaceuticals Co., LTD.
(Brise), a pioneering company specializing in innovative treatments
for acute and chronic pain, has recently completed Pre-A and
Pre-A+ financing with a total of approximately $20 million. This Pre-A round is led by Shunxi
Fund, followed by Cnfuel Capital, Vinner Therapeutics and existing
investors such as Qiming Venture
Partners and BioTrack Capital. The Pre-A+ round is
exclusively invested by Sherpa Healthcare Partners.
Brise has advanced two molecules to the clinical stage in US and
China. The funds raised will be
used to advance the company's product pipeline in the preclinical
and clinical stages, as well as to further refine and validate the
Trigeminovascular System (TVS) biology-based drug development
platform and the Dorsal Root Ganglion (DRG) biology-based drug
development platform.
Brise, led by CEO Dr. Guochun Li,
stands as a clinical-stage biopharmaceutical company with a
singular focus on the development of innovative and highly
differentiated analgesic treatments for debilitating pain
conditions with large unmet needs, placing a particular emphasis on
addressing migraine, neuropathic and musculoskeletal pain.
The organization's vision is to provide safe, effective, and
accessible pain relief solutions for the multitude of patients
worldwide grappling with poorly managed pain conditions.
View original
content:https://www.prnewswire.com/news-releases/brise-pharmaceuticals-raises-nearly-20m-in-series-pre-a-and-pre-a-financing-302123069.html
SOURCE Brise Pharmaceuticals Co., Ltd